Economic Modelling
Cost-Effectiveness Modelling
and Budget Impact Modelling
At SHE, we use 50+ years of combined Health Technology Assessment experience to develop tailored, precise and flexible health economic models:​​​
AUDIENCE:
-
For HTA submission or Global models
-
Early models to inform go/no go decisions
-
Model adaptations for affiliates
​
ANALYSIS TYPE:
-
Markov Cohort models, partitioned survival models or simulation models
-
Budget Impact models for EU or US
APPLICATION:
-
In MS Excel or R
-
User-friendly interface with buttons and drop-down menus
-
Including probabilistic sensitivity analysis
-
Seamless integration of the Phase 3 trial data analysis
Disease Areas with Modelling Experience
Oncology
Lymphoma, advanced melanoma, cervical cancer, breast cancer, prostate cancer, stem cell transplantation, NSCLC​
Cardiovascular
CHD/CVD, stroke, atherosclerosis, hypercholesterolemia, angiogenesis, hypertension, PAOD, stents, atrial fibrillation​
Gastro-intestinal
Ulcerative colitis, Crohn’s disease, GORD, nutritional supplements, over-active bladder​
Central nervous system
Myasthenia Gravis, MS, ADHD, epilepsy
Orphan diseases
CIDP, HLH, IPF, MG, Gaucher’s disease, Pompe, severe pain
Auto-immune
Rheumatoid arthritis, psoriatic arthritis
Respiratory
Asthma, COPD